ArticleArchives of public health = Archives belges de sante publique2026
Estimating the incidence of SARS-CoV-2 infections by jointly modelling seroprevalence, hospitalization and mortality data, February 2020 - January 2021, Belgium.
Article in Archives of public health = Archives belges de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBelgium experienced two SARS-CoV-2 epidemic waves in 2020, in spring and autumn. Due to limited testing capacity, restrictive case definitions, asymptomatic infections, and incomplete testing compliance, case counts represent only a lower bound of SARS-CoV-2 infection incidence. We estimated this incidence from February 2020 to January 2021 by jointly modelling seroprevalence and surveillance data.
methodsWe developed a hierarchical Bayesian model that jointly fits seroprevalence, hospitalization, and mortality data to a shared latent incidence curve, represented by a spline. The model accounts for time-varying serological test sensitivity (reflecting seroconversion and seroreversion) using informative priors, and simultaneously estimates test specificity, infection-to-event distributions, and time-varying infection hospitalization rates (IHR) and infection fatality rates (IFR). Seroprevalence data comprised 37,235 samples from two repeated cross-sectional studies: residual laboratory samples tested with the EuroImmun IgG ELISA and blood donor samples tested with the Wantai Ab ELISA. Hospitalization and mortality counts were obtained from national COVID-19 surveillance.
resultsBy early 2021, an estimated 19.0% (95% Credible Interval (CrI) 17.4-20.7), 13.6% (CrI 11.5-15.8) and 10.8% (CrI 8.7-13.2) of the Belgian 18-49, 50-64 and 65-74 year-olds had been infected with SARS-CoV-2. The first wave mostly affected the younger age group, with a peak weekly incidence of 2.0% (CrI 1.7-2.3) late March 2020. The second wave peaked late October 2020 with weekly incidences of 1.6% (CrI 1.2-2.1) among 65-74 year-olds and 2.8% (CrI 2.4-3.3) among 18-49 year-olds. IHR and IFR were considerably higher in older age groups and declined over time. Among 65-74 year-olds IHR declined from 9.9% (CrI 7.3-14.2) to 5.0% (CrI 3.5-7.1) and IFR from 2.8% (CrI 2.0-4.0) to 1.2% (CrI 0.9-1.7).
conclusionAn estimated 16.3% (CrI 15.1-17.4) of the Belgian adult population had been infected with SARS-CoV-2 by early 2021. Joint modelling of seroprevalence and surveillance data provides a framework for estimating infection burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.